Commitments and Contingencies - Additional Information (Detail) - USD ($) $ in Millions |
3 Months Ended | 9 Months Ended | |
|---|---|---|---|
Mar. 05, 2021 |
Jun. 30, 2024 |
Sep. 30, 2024 |
|
| Commitments And Contingencies [Line Items] | |||
| Estimated service fees, pass through expenses, and investigator fees | $ 44.7 | ||
| Maximum earnings in milestone payment | $ 4.8 | ||
| Estimated Service Fees | $ 26.4 | ||
| Active Pharmaceutical Ingredients [Member] | |||
| Commitments And Contingencies [Line Items] | |||
| Agreement description | Under a manufacture and supply agreement with an active pharmaceutical ingredients (“API”) manufacturer for molgramostim, as amended, the Company must make certain payments to the API manufacturer upon achievement of the milestones outlined in the table set forth below. Additionally, upon first receipt of marketing approval by the Company from a regulatory authority in a country for a product containing the API for therapeutic use in humans and ending the earlier of (i) ten (10) years thereafter or (ii) the date a biosimilar of such product is first sold in such country, the Company shall pay the API manufacturer a royalty equal to low-single digits of the net sales in that country of products containing API supplied by the API manufacturer. | ||
| Second Source Member | Maximum [Member] | |||
| Commitments And Contingencies [Line Items] | |||
| Percentage of cancellation fees | 100.00% | ||
| Second Source Member | Minimum [Member] | |||
| Commitments And Contingencies [Line Items] | |||
| Percentage of cancellation fees | 10.00% | ||
| Nebulizer [Member] | |||
| Commitments And Contingencies [Line Items] | |||
| Royalty percent on net sale | 3.50% |